EcoDrugPlus

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSOTSG00005029079
Gene Symbol: HTR3A
1 Cross references
193 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSOTSG00005013864
Gene Symbol: HTR3B
1 Cross references
170 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSOTSG00005011331
Gene Symbol: HTR4
3 Cross references
193 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSOTSG00005011484
Gene Symbol: HTR4
3 Cross references
193 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSOTSG00005009279
Gene Symbol: HTR5A
1 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSOTSG00005044843
Gene Symbol: HTR5A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSOTSG00005023602
Gene Symbol: HTR7
1 Cross references
147 Possible Orthologues:

60s Ribosomal Protein L10a

Ensembl ID : ENSOTSG00005031461
Gene Symbol: LOC112244790
3 Cross references
363 Possible Orthologues:

60s Ribosomal Protein L11

Ensembl ID : ENSOTSG00005008752
Gene Symbol: LOC112264863
3 Cross references
282 Possible Orthologues:

60s Ribosomal Protein L13-Like

Ensembl ID : ENSOTSG00005029606
Gene Symbol: LOC112249162
3 Cross references
269 Possible Orthologues:

60s Ribosomal Protein L13a

Ensembl ID : ENSOTSG00005036858
Gene Symbol: LOC112262058
3 Cross references
363 Possible Orthologues:

60s Ribosomal Protein L14-Like

Ensembl ID : ENSOTSG00005027076
Gene Symbol: LOC112264506
3 Cross references
303 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).